Q-Med sees continued weak deliveries to North America and Japan

Q-Med sees continued weak deliveries to North America and Japan 

Q-Med sees continued weak deliveries of esthetic products to North America and
Japan during the first quarter of 2008. Deliveries of esthetic products to North
America are probably still being affected by the building up of inventories that
occurred during the second and third quarters last year. Deliveries to Japan are
being affected both by insufficient processing of the market as a consequence of
the fact that Q-Med cannot be actively present in the Japanese market and by the
fact that sales to one of the major customers are still being affected
negatively as a consequence of the customer's previous payment problems. 

The continued weak development with regard to deliveries to these markets in
combination with continued investments in marketing and sales has affected
income for the first quarter negatively.

It is estimated that Q-Med's total sales were 289 MSEK during the first quarter
and that operating income was 10 MSEK.

Investments in marketing and sales comprise amongst other things the launch of
Macrolane™ and increased sales work in the European market. 

In the longer term, however, Q-Med is positive to how the market and demand for
Q-Med's products will develop. Q-Med's overall objective is continued high
growth together with good profitability. 


Queries should be addressed to: 
Bengt Ågerup, President and CEO
Tel: +46 (0)70-974 9025
Alexander Kotsinas, CFO
Tel: +46 (0)70-974 9020
Madelene Sandgren, Director Investor Relations and Corporate Communications
Tel: +46 (0)70-974 9015

Q-Med's interim report January-March will be published April 29.

The information was submitted for disclosure at 7.55 a.m. on April 11.

Q-Med AB is a rapidly growing and profitable biotechnology/medical device
company. The company develops, manufactures, markets, and sells primarily
medical implants. The majority of the products are based on the company's
patented technology, NASHA™, for the production of stabilized non-animal
hyaluronic acid. The product portfolio today contains: Restylane® for filling
lines and folds, contouring and creating volume in the face, Macrolane™ for body
contouring, Durolane™ for the treatment of osteoarthritis of the hip and knee
joints, Deflux® for the treatment of vesicoureteral reflux, VUR, (a malformation
of the urinary bladder) in children, and Solesta™ for the treatment of fecal
incontinence. Sales are made through the company's own subsidiaries or
distributors in over 70 countries. Q Med today has just over 700 coworkers, with
close to 500 at the company's head office and production facility in Uppsala,
Sweden. Q-Med AB is listed in the Mid Cap segment of the OMX Nordic Exchange in
Stockholm.

Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate
identity number 556258-6882.
Tel: +46(0)18-474 90 00. Fax: +46(0)18-474 90 01. E-mail: info@q-med.com. Web:
www.q-med.com.

In USA, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med Scandinavia,
Inc